L
Leila A. Kutteh
Researcher at Mayo Clinic
Publications - 25
Citations - 6391
Leila A. Kutteh is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Breast cancer & Trastuzumab. The author has an hindex of 14, co-authored 25 publications receiving 6066 citations. Previous affiliations of Leila A. Kutteh include Case Western Reserve University.
Papers
More filters
Journal ArticleDOI
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more
TL;DR: Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.
Journal ArticleDOI
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Ravi D. Rao,John C. Michalak,Jeff A. Sloan,Charles L. Loprinzi,Gamini S. Soori,Daniel A. Nikcevich,David O. Warner,Paul J. Novotny,Leila A. Kutteh,Gilbert Y. Wong +9 more
TL;DR: A multicenter, double‐blind, placebo‐controlled, crossover, randomized trial was conducted to evaluate the effect of gabapentin on symptoms of chemotherapy‐induced peripheral neuropathy (CIPN).
Journal ArticleDOI
Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831
Michele Y. Halyard,Thomas M. Pisansky,Amylou C. Dueck,Vera J. Suman,Lori J. Pierce,L. J. Solin,Lawrence B. Marks,Nancy E. Davidson,Silvana Martino,Peter A. Kaufman,Leila A. Kutteh,Shaker R. Dakhil,Edith A. Perez +12 more
TL;DR: Concurrent adjuvant RT and H for early-stage BC was not associated with increased acute AEs, and further follow-up is required to assess late AEs.
Journal ArticleDOI
Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial
Kostandinos Sideras,Paul L. Schaefer,Scott H. Okuno,Jeff A. Sloan,Leila A. Kutteh,Tom R. Fitch,S. R. Dakhil,Ralph Levitt,Steven R. Alberts,Roscoe F. Morton,Kendrith M. Rowland,Paul J. Novotny,Charles L. Loprinzi +12 more
TL;DR: This trial was unable to demonstrate any survival benefit for LMWH in patients with advanced cancer.
Journal ArticleDOI
Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial
Edith A. Perez,Amylou C. Dueck,Ann E. McCullough,Beiyun Chen,Xochiquetzal J. Geiger,Robert B. Jenkins,Wilma L. Lingle,Nancy E. Davidson,Silvana Martino,Peter A. Kaufman,Leila A. Kutteh,George W. Sledge,Lyndsay Harris,Julie Gralow,Monica M. Reinholz +14 more
TL;DR: Benefit of adjuvant trastuzumab for patients with HER2-positive breast cancer, independent of tumor PTEN status is shown, in contrast to selected preclinical and limited clinical studies suggesting a decrease in trastizumab sensitivity.